The legal action, captioned Mazzarino v. ADMA Biologics, Inc., et al., alleges that senior executives violated federal securities laws by misrepresenting the company's financial health. According to the complaint, ADMA reported 20% growth for 2025, a figure plaintiffs claim was fabricated through a scheme involving undisclosed related-party transactions and the forced accumulation of excess inventory by distributors.
In section Releases
Investors Face August Deadline in ADMA Biologics Securities Lawsuit
Investors in ADMA Biologics have until August 10, 2026, to petition the U.S. District Court for the District of New Jersey for lead plaintiff status in a pending class action lawsuit. The litigation follows accusations that the biopharmaceutical company artificially inflated its revenue through deceptive channel stuffing practices.
The volatility in ADMA’s stock price began on March 24, 2026, after Culper Research published a report alleging that the company’s flagship product, ASCENIV, faced waning demand. The report contended that ADMA offered rebates and extended payment terms to distributors to secure orders, masking what would have otherwise been a 3% decline in revenue. Following the publication, shares fell 16.6% in a single day, with further losses compounded by a subsequent downgrade from Cantor. The firm Bleichmar Fonti & Auld LLP is representing investors seeking to recover losses, noting that all representation is conducted on a contingency basis.
Comments (0)
No comments yet. Be the first!